HOME JOURNALS CONTACT

International Journal of Pharmacology

Year: 2005 | Volume: 1 | Issue: 1 | Page No.: 17-24
DOI: 10.3923/ijp.2005.17.24
Biologic Management of Fistulizing Crohn’s Disease
Ali Rezaie, Bardia Taghavi Bayat and Mohammad Abdollahi

Abstract: Fistulas, occurring in about 20 to 40% of Crohn’s disease patients, are usually resistant to conventional therapy of CD. Biologic therapies, which have revolutionary beneficial effects on diseases with an immunologic background, are a new horizon in treating fistulizing CD. The aim of this study was to evaluate the efficacy of biologic agents used to treat fistulizing CD after a brief overview on epidemiology and pathophysiology of fistulizing CD and definition of biologic therapy. Also it focuses on the trials and adverse effects of the biologic agents proved to be effective (Infliximab and CDP571).

Fulltext PDF

How to cite this article
Ali Rezaie, Bardia Taghavi Bayat and Mohammad Abdollahi, 2005. Biologic Management of Fistulizing Crohn’s Disease. International Journal of Pharmacology, 1: 17-24.

Keywords: . and .

REFERENCES
  • Griffiths, A. and H. Buller, 2000. Inflammatory Bowel Disease. In: Pediatric Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, Walker, WA., J.R. Hamilton, J.A. Walker-Smith and J.B. Watkins (Eds.). BC Decker, Hamilton, Ontario, pp: 613

  • Farmer, R.G., W.A. Hawk and R.B. Jr. Turnbull, 1975. Clinical patterns in Crohn's disease: A statistical study of 615 cases. Gastroenterology, 68: 627-635.
    PubMed    Direct Link    

  • Lapidus, A., O. Bernell, G. Hellers and R. Lofburg, 1998. Clinical course of colorectal Crohn's disease: A 35-year follow-up study of 507 patients. Gastroenterology, 114: 1151-1160.
    CrossRef    Direct Link    

  • Sands, B.E., F.H. nderson, C.N. Bernstein, W.Y. Chey and B.G. Feagan et al., 2004. Infliximab maintenance therapy for fistulizing crohn's disease. N. Engl. J. Med., 350: 876-885.
    Direct Link    

  • Sachar, D.B., 1995. Maintenance therapy in ulcerative colitis and Crohn's disease. J. Clin. Gastroenterol., 20: 117-122.
    Direct Link    

  • Sandborn, W.J. and S.R. Targan, 2002. Biologic therapy of inflammatory bowel disease. Gastroenterology, 122: 1592-1608.
    PubMed    Direct Link    

  • Sands, B.E., 1997. Biologic therapy for inflammatory bowel disease. Inflamm. Bowel. Dis., 3: 95-113.

  • Sandborn, W.J. and S.B. Hanauer, 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results and safety. Inflammat. Bowel Dis., 5: 119-133.
    PubMed    Direct Link    

  • Papadakis, K.A. and S.R. Targan, 2000. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology, 119: 1148-1157.
    PubMed    Direct Link    

  • Podolsky, D.K., 2002. Medical progress: Inflammatory bowel disease. N. Engl. J. Med., 347: 417-429.
    Direct Link    

  • Elson, C.O., 2002. Genes, microbes and T cells new therapeutic targets in Crohn's disease. N. Engl. J. Med., 346: 614-616.
    Direct Link    

  • Keane, J., H.G. Remold and H. Kornfeld, 2000. Virulent mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J. Immunol., 164: 2016-2020.
    PubMed    Direct Link    

  • Sandborn, W.J., S.B. Hanauer, S. Katz, M. Safdi and D.G. Wolf et al., 2001. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology, 121: 1088-1094.
    PubMed    Direct Link    

  • Schreiber, S., P. Rutgeerts, R. Fedorak, M. Khaliq-Kareemi, M.A. Kamm and J. Patel, 2003. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's Disease (CD). Gastroenterology, 124: A61-A61.
    Direct Link    

  • Sandborn, W.J., B.G. Feagan and S.B. Hanauer, D.H. Present and L.R. Sutherland et al., 2001. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology, 120: 1330-1338.
    PubMed    Direct Link    

  • Sandborn, W., B. Feagan, G. Radford-Smith, A. Kovacs, R. Enns and J.A. Patel, 2003. Randomized, placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-a, in patients with moderate to severe Crohn's disease. Gastroenterology, 124: A-61.

  • Shen, C., P. Maerten, G. van Assche, K. Geboes, P. Rutgeerts and J. Ceuppens, 2004. A fully human anti-TNF mAb adalimumab (D2E7) induces caspase-dependent apoptosis of human peripheral blood monocytes and T cells. Gastroenterology, 126: A153-A153.
    Direct Link    

  • Van Deventer, S., 2004. Anti-TNF mechanisms of action: From bench to bedside-AGA state of the art lecture. Program and Abstracts of Digestive Disease Week New Orleans, Louisiana, pp: 15-20.

  • Mannon, P., I. Fuss, L. Mayer, C.O. Elson and W.J. Sandborn et al., 2004. Anti-interleukin-12 treats active Crohn's disease. N. Engl. J. Med., 351: 2069-2079.
    PubMed    Direct Link    

  • Hommes, D., T. Mikhajlova, S. Stoinov, D. Stimac and B. Vucelic et al., 2004. Fontolizumab (HuZAFJ), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn's Disease Gastroenterology, 127: 332-332.
    Direct Link    

  • Ito, H., M. Takazoe, Y. Fukuda, H. Toshifumi and K. Kazuo et al., 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology, 126: 989-996.
    CrossRef    Direct Link    

  • Ghosh, S., E. Goldin, F.H. Gordon, M.A. Helmut and M.A. Helmut et al., 2003. Natalizumab for active Crohn's disease. N. Engl. J. Med., 348: 24-32.
    Direct Link    

  • Plevy, S.E., B.A. Salzberg and M. Regueiro, 2003. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study. Gastroenterology, 124: A7-A7.

  • Dieckgraefe, B.K., 2003. Sargramostim (Leukine) induces response and remission in moderately to severely activated Crohn's Disease: Results from the first randomized double-blind placebo-controlled trial. Proceedings of the 68th Annual Scientific Meeting of American College of Gastroenterology, Oct. 14-14, Baltimore, Maryland.

  • Weinstock, J.V., R. Summers and D.E. Elliott, 2004. Helminths and harmony. Gut, 53: 7-9.
    CrossRef    Direct Link    

  • Summers, R.W., D.E. Elliott and R. Thompson, 2004. Double-blind, placebo-controlled trial of helminth ova therapy in active ulcerative colitis. Gastroenterology, 126: A83-A83.

  • Summers, R.W., D.E. Elliott and R. Thompson et al., 2004. Trial of helminth ova in active Crohn's disease. Gastroenterology, 126: A75-A75.

  • Van Deventer, S.J.H., 1997. Tumour necrosis factor and Crohn's disease. Gut, 40: 443-448.
    PubMed    Direct Link    

  • Brynskov, J., O.H. Nielsen, I. Ahnfelt-Ronne and K. Bendtzen, 1994. Cytokines (Immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Dig. Dis., 12: 290-304.
    CrossRef    Direct Link    

  • Braegger, C.P., S. Nicholls, S.H. Murch, T.T. MacDonald and S. Stephens, 1992. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 339: 89-91.
    CrossRef    Direct Link    

  • Reimund, J.M., C. Wittersheim, S. Dumont, C.D. Muller, R. Baumann, P. Poindron and B. Duclos, 1996. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. J. Clin. Immunol., 16: 144-150.
    CrossRef    Direct Link    

  • Breese, E.J., C.A. Michie, S.W. Nicholls, S.H. Murch and C.B. Williams et al., 1994. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology, 106: 1455-1466.
    Direct Link    

  • Feldmann, M., F.M. Brennan and R.N. Maini, 1996. Rheumatoid arthritis. Cell, 85: 307-310.

  • Knight, D.M., H. Trinh, J. Le, S. Siegel and D. Shealy et al., 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol., 30: 1443-1453.
    PubMed    Direct Link    

  • Scallon, B.J., M.A. Moore, H. Trinh, D.M. Knight and J. Ghrayeb, 1995. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine, 7: 251-259.
    CrossRef    Direct Link    

  • Siegel, S.A., D.J. Shealy, M.T. Nakada, J. Le and D.S. Woulfe et al., 1995. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine, 7: 15-25.
    PubMed    Direct Link    

  • Van den Brande, J.M., H. Braat, G.R. van den Brink, H.H. Versteeg and C.A. Bauer et al., 2003. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology, 124: 1774-1785.
    PubMed    Direct Link    

  • Plevy, S.E., C.J. Landers, J. Prehn, N.M. Carramanzana, R.L. Deem, D. Shealy and S.R. Targan, 1997. A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J. Immunol., 159: 6276-6282.

  • Present D.H., P. Rutgeerts, S. Targan, S.B. Hanauer and L. Mayer et al., 1999. Infliximab for the treatment of fistulas in patients with Crohn`s disease. N. Engl. J. Med., 340: 1398-1405.
    Direct Link    

  • Sands B., S. Van Deventer, C. Bernstein, M. Kamm and D. Rachmilewicz et al., 2002. Long-term treatment of fistulizing Crohn`s disease: Response to infliximab in the ACCENT II trial through 54 weeks. Gastroenterology, 122: A81-A81.

  • Regueiro, M. and H. Mardini, 2003. Treatment of perianal fistulizing Crohn`s disease with infliximab alone or as an adjunct for exam under anesthesia with seton placement. Inflammat. Bowel Dis., 9: 98-103.
    PubMed    Direct Link    

  • Koganei, K., A. Sugita, H. Harada, T. Fukushima and H. Shimada, 1995. Seton treatment for perianal Crohn's fistulas. Surg. Today, 25: 32-36.
    CrossRef    Direct Link    

  • Hanauer, S.B., B.G. Feagan, G.R. Lichtenstein, L.F. Mayer and S. Schreiber et al., 2002. ACCENT I study group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet, 359: 1541-1549.
    PubMed    Direct Link    

  • Colombel, J.F., E.V. Loftus Jr, W.J. Tremaine, L.J. Egan and W.S. Harmsen et al., 2004. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology, 126: 19-31.
    PubMed    Direct Link    

  • Farrell, R.J., S.A. Shah, P.J. Lodhavia, M. Alsahli, K.R. Falchuk, P. Michetti and M.A. Peppercorn, 2000. Clinical experience with infliximab therapy in 100 patients with Crohn`s disease. Am. J. Gastroenterol., 95: 3490-3497.
    PubMed    Direct Link    

  • Vermeire, S., M. Norman, G. Van Assche, N. Esters and S. Joossens et al., 2001. Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation. Gastroenterology, 120: A69-A69.

  • Mohan, N., E.T. Edwards, T.R. Cupps, P.J. Oliverio and G. Sandberg et al., 2001. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum, 44: 2862-2869.
    Direct Link    

  • Tartaglia, L.A. and D.V. Goeddel, 1992. Two TNF receptors. Immunol. Today, 13: 151-153.
    PubMed    Direct Link    

  • Pryhuber, G.S., H.L. Huyck, R.J. Staversky, J.N. Finkelstein and M.A. O'Reilly, 2000. Tumor necrosis factor-α-induced lung cell expression of antiapoptotic genes TRAF1 and cIAP2. Am. J. Respiratory Cell Mol. Biol., 22: 150-156.

  • Fratazzi, C., R.D. Arbeit, C. Carini and H.G. Remold, 1997. Programmed cell death of Mycobacterium avium serovar 4-infected human macrophages prevents the mycobacteria from spreading and induces mycobacterial growth inhibition by freshly added, uninfected macrophages. J. Immunol., 158: 4320-4327.
    Direct Link    

  • Keane, J., S. Gershon, R.P. Wise, E. Mirabile-Levens and J. Kasznica et al., 2001. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med., 345: 1098-1104.
    Direct Link    

  • Feagan, B.G., W.J. Sandborn, J. Baker, F. Cominelli and L.R. Sutherland et al., 2000. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology, 118: A655-A655.

  • Sandborn, W.J., B.G. Feagan and S.B. Hanauer, D.H. Present and L.R. Sutherland et al., 2001. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology, 120: 1330-1338.
    PubMed    Direct Link    

  • Jahanshahi, G., V. Motavasel, A. Rezaie, A.A. Hashtroudi, N.E. Daryani and M. Abdollahi, 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci., 49: 1752-1757.
    CrossRef    PubMed    Direct Link    

    • © Science Alert. All Rights Reserved